The In Vivo Gene Therapy Market was valued at USD 5.43 Billion in 2024 and reached USD 6.50 Billion in 2025. The market is projected to expand to USD 32.50 Billion by 2034, registering a CAGR of 19.6% during the forecast period 2026–2034. This represents an absolute dollar opportunity of USD 26.00 Billion across the analysis window. The market spans approved AAV-based, lentiviral, adenoviral, and HSV-1-based gene therapies delivered directly to patients without ex vivo cell modification, plus the broader pipeline of in vivo CAR-T, in vivo CRISPR base editing, and lipid nanoparticle (LNP)-delivered gene therapies addressing oncology, hematology, neurology, ophthalmology, and rare disease indications.
In Vivo Gene Therapy Market Global Forecast to 2034 (USD)
CAGR OF
19.6%
In Vivo Gene Therapy Market
USD 5.43 BUSD 6.50 BUSD 32.50 B
Get more details on this report -
In vivo administration captured the largest share of the broader gene therapy market in 2025, accounting for approximately 67% of revenue across hemophilia, spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and inherited retinal disease franchises. AAV vectors anchored 75% of in vivo delivery, supported by hepatocyte tropism for liver-directed therapies and emerging CNS-targeted capsids including AAV-PHP.B and AAV9 derivatives. Approved products driving 2025 revenue include Novartis Zolgensma (onasemnogene abeparvovec) for SMA, Sarepta Elevidys (delandistrogene moxeparvovec) for DMD, Spark Luxturna (voretigene neparvovec) for RPE65-mutation retinal dystrophy, CSL Behring Hemgenix (etranacogene dezaparvovec) for hemophilia B, and BioMarin Roctavian (valoctocogene roxaparvovec) for hemophilia A.
Demand growth is anchored by three structural forces. First, accelerated approvals: the U.S. FDA cleared three new in vivo gene therapies through 2025, including Encelto from Neurotech Pharmaceuticals during March 2025 for macular telangiectasia type 2 and Papzimeos from Precigen during August 2025 for HPV-related recurrent respiratory papillomatosis. Second, capital migration toward in vivo platforms: AstraZeneca's USD 1 Billion absorption of EsoBiotec announced 17 March 2025 and closed Q2 2025 anchors blue-chip pharma commitment, joined by Stylus Medicine's USD 85 Million launch capital during May 2025. Third, manufacturing scale-up: AAV manufacturing service capacity reached USD 1.44 Billion in 2025 supply, projected to climb to USD 6.25 Billion by 2035.
North America led the in vivo gene therapy market with approximately 45.0% share in 2025, anchored by FDA-approved product franchises, the highest concentration of biotech capital, and hospital-and-academic-medical-center delivery infrastructure. The United States generated USD 2.65 Billion in 2025 in vivo gene therapy revenue. Europe captured 28.5% share, propelled by EMA-approved label coverage for Zolgensma, Luxturna, Roctavian, Hemgenix, Elevidys, and Kebilidi across Germany, France, the United Kingdom, Italy, and Spain. Asia Pacific accounted for 17.0% but is the fastest-growing region at a projected 28.8% CAGR through 2034, supported by Japan's Act on the Safety of Regenerative Medicine, China's National Medical Products Administration accelerated pathways, and India's CDSCO biosimilar gene therapy framework.
Forward to 2034, three structural shifts will define winners: in vivo CAR-T and in vivo CRISPR base editing will outpace traditional viral vector therapies as AstraZeneca, Stylus Medicine, and Verve Therapeutics commercialize platform programs that bypass autologous manufacturing bottlenecks; engineered capsid programs (AAV-PHP.B for CNS delivery, capsids designed to evade pre-existing immunity) will absorb the rising share of neurodegenerative-indication procurement; and outcomes-based reimbursement models will become standard for one-time-curative pricing, replacing flat-rate launch pricing that has constrained Roctavian and Hemgenix uptake despite regulatory clearance.
Market Definition & Scope
The in vivo gene therapy market is defined as therapies that deliver functional genes, gene-editing components, or gene-silencing payloads directly to a patient's body via systemic intravenous infusion, intramuscular injection, intrathecal delivery, subretinal injection, or topical application, without ex vivo cell extraction or modification. The market spans AAV-vector-based therapies, lentiviral-vector in vivo platforms, adenoviral therapies, HSV-1-based topical gene therapies, lipid nanoparticle (LNP)-delivered mRNA gene therapies, and the emerging in vivo CRISPR base editing pipeline.
This analysis includes commercialized in vivo gene therapy products, late-stage clinical assets within 24 months of expected approval, AAV manufacturing and viral vector production capacity, and LNP-and-engineered-capsid delivery platforms. Excluded from scope are ex vivo cell-and-gene therapies (Casgevy, Lyfgenia, Kymriah, Yescarta, Carvykti, Lenmeldy), siRNA-only therapies marketed as gene silencing without DNA modification, gene therapy clinical trial services billed independently of the therapy itself, and CAR-T platforms manufactured outside the patient. The in vivo gene therapy market is a sub-segment of the broader USD 11.07 Billion gene therapy market and represented approximately 59% of total gene therapy value in 2025.
Key Takeaways
Market Growth: The in vivo gene therapy market expanded from USD 6.50 Billion in 2025 toward a projected USD 32.50 Billion by 2034, registering a 19.6% CAGR.
Segment Dominance (Vector): AAV vectors captured 75.0% of 2025 in vivo gene therapy revenue, ahead of lentiviral vectors at 12.0% and lipid nanoparticles at 8.0%.
Segment Dominance (Indication): Hematology and rare blood disorders represented 32.0% of 2025 in vivo gene therapy revenue, ahead of neuromuscular disorders at 28.0% and ophthalmology at 14.0%.
Driver: FDA accelerated-approval pathways cleared Encelto (March 2025) and Papzimeos (August 2025), expanding the approved in vivo gene therapy menu by two products in a single year.
Restraint: Pre-existing anti-AAV5 antibodies excluded approximately 35% of potential Roctavian patients per BioMarin's multinational seroprevalence study, capping addressable populations across AAV-based franchises.
Opportunity: In vivo CAR-T platforms unlock a USD 4.50 Billion incremental opportunity by 2034, building on AstraZeneca's EsoBiotec ENaBL platform and Stylus Medicine's May 2025 launch.
Trend: AAV manufacturing service capacity reached USD 1.44 Billion in 2025 and is projected to climb to USD 6.25 Billion by 2035 at a 15.7% CAGR, sharpening supply-side scaling.
Regional: North America led the in vivo gene therapy market with 45.0% share and USD 2.93 Billion in 2025 revenue, anchored by FDA-approved franchises and U.S. biotech capital.
Key Insights Summary
On 17 March 2025, AstraZeneca disclosed the take-up of Belgian biotech EsoBiotec for up to USD 1 Billion (USD 425 Million upfront plus USD 575 Million milestone-contingent), closing during Q2 2025.
During May 2025, Stylus Medicine launched with USD 85 Million in capital to advance precision in vivo genetic therapies and scaled in vivo CAR-T platform programs.
On March 2025, Neurotech Pharmaceuticals received U.S. FDA clearance for Encelto (revakinagene taroretcel) for macular telangiectasia type 2, expanding the approved in vivo therapy roster.
On August 2025, Precigen earned U.S. FDA clearance for Papzimeos (zopapogene imadenovec) for HPV-related recurrent respiratory papillomatosis, the second 2025 in vivo gene therapy approval.
On September 2024, Vironexis Biotherapeutics earned FDA Investigational New Drug clearance for the first AAV-delivered cancer immunotherapy clinical trial, opening an oncology lane for in vivo platforms.
Pre-existing anti-AAV5 antibodies in approximately 35% of multinational populations per BioMarin's seroprevalence study cap addressable populations for AAV5-based therapies, including Roctavian and Hemgenix.
During February 2025, Andelyn Biosciences broadened its AAV Curator platform via Stanton Lab CNS capsid licensing, supporting external R&D services for client gene therapy programs.
Competitive Landscape Overview
The in vivo gene therapy market is moderately concentrated, with the top four players (Novartis, Roche/Spark, Sarepta, AstraZeneca) collectively holding an estimated 48% of 2025 revenue. The structure splits across three lanes: AAV-based incumbents commercializing approved one-time-curative therapies (Novartis Zolgensma, Sarepta Elevidys, Spark Luxturna, BioMarin Roctavian, CSL Behring Hemgenix, PTC Kebilidi); blue-chip pharma platform builders investing in in vivo CAR-T and engineered capsids (AstraZeneca via EsoBiotec, Roche via Spark, Pfizer's prior investments before its 2025 exit); and venture-backed in vivo specialists (uniQure, Regenxbio, Krystal Biotech, Stylus Medicine, Vironexis Biotherapeutics, 4D Molecular Therapeutics, Voyager Therapeutics, Verve Therapeutics).
Competition is restructuring around manufacturing economics rather than scientific novelty alone. Pfizer's exit from gene therapy during 2025, including Beqvez discontinuation, signals that approval alone does not guarantee commercial success when patient identification and reimbursement frameworks underdeliver. Slow market uptake at Roctavian and Hemgenix despite full approvals validates this thesis. Vertical integration through M&A (AstraZeneca-EsoBiotec, Roche's continued Spark investment) is the dominant scaling strategy among large pharma. AAV manufacturing capacity scaling at Catalent, Lonza, Andelyn Biosciences, and Forge Biologics anchors the supply-side competitive landscape.
Company
HQ
Position
Key Product
Geographic Strength
Recent Strategic Move
Novartis AG
Switzerland
Leader
Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy
Global
Continued Zolgensma label expansion across European markets 2025
Roche / Spark Therapeutics
Switzerland / U.S.
Leader
Luxturna (voretigene neparvovec) for RPE65 retinal dystrophy
North America, EU
Sustained Luxturna commercial rollout under Roche Pharma 2025
Sarepta Therapeutics
United States
Leader
Elevidys (delandistrogene moxeparvovec) for Duchenne muscular dystrophy
North America, EU, Japan
Broadened Elevidys label coverage during 2024-2025
AstraZeneca plc
United Kingdom
Leader
EsoBiotec ENaBL in vivo lentiviral platform
Global
Closed EsoBiotec take-up valued up to USD 1 Billion Q2 2025
CSL Behring
United States
Challenger
Hemgenix (etranacogene dezaparvovec) for hemophilia B
North America, EU
Continued Hemgenix patient enrollment progress through 2025
BioMarin Pharmaceutical
United States
Challenger
Roctavian (valoctocogene roxaparvovec) for hemophilia A
Continued Vyjuvek commercial expansion during 2025
Precigen, Inc.
United States
Niche Player
Papzimeos (zopapogene imadenovec) for HPV recurrent disease
North America
Earned U.S. Papzimeos clearance during August 2025
Neurotech Pharmaceuticals
United States
Niche Player
Encelto (revakinagene taroretcel) for macular telangiectasia
North America
Earned U.S. Encelto clearance during March 2025
By Vector Type
AAV (adeno-associated virus) vectors dominated the in vivo gene therapy market with 75.0% of 2025 revenue, anchored by AAV9 (Zolgensma, Elevidys), AAV5 (Roctavian, Hemgenix, Beqvez before discontinuation), AAV2 (Luxturna, Kebilidi), and engineered AAV-PHP.B for CNS delivery. Lentiviral vectors held 12.0% share for in vivo applications, propelled by AstraZeneca's EsoBiotec ENaBL platform and pipeline in vivo CAR-T programs. Lipid nanoparticles captured 8.0%, projected to grow fastest at 23.4% CAGR through 2034 as Moderna, BioNTech, and other LNP developers advance gene editing payloads. HSV-1 vectors (Krystal Biotech Vyjuvek, Amgen Imlygic) covered 3.0%, and adenoviral and other vectors the residual 2.0%.
By Indication
Hematology and rare blood disorders led the in vivo gene therapy market with 32.0% of 2025 indication revenue, anchored by Hemgenix and Roctavian for hemophilia A and B. Neuromuscular disorders captured 28.0%, propelled by Zolgensma for SMA (now the largest single in vivo gene therapy product) and Elevidys for DMD. Ophthalmology accounted for 14.0%, with Luxturna and Encelto serving inherited retinal disease and macular telangiectasia. Oncology captured 12.0%, projected to grow fastest at 22.7% CAGR through 2034 as in vivo CAR-T platforms commercialize. Metabolic and rare-disease indications covered 8.0%, neurodegenerative disorders 4.0%, and other indications (HPV, dermatology) the residual 2.0%.
By Route of Administration
Intravenous (systemic) administration represented 46.0% of 2025 in vivo gene therapy revenue, anchored by Zolgensma, Hemgenix, Roctavian, and Elevidys delivered through single-infusion liver- or muscle-targeted approaches. Intramuscular injection captured 18.0%, supported by limb-girdle and other muscular dystrophy programs. Subretinal and intravitreal injection accounted for 14.0%, propelled by Luxturna and Encelto. Intrathecal delivery represented 10.0%, growing at 25.2% CAGR through 2034 as CNS-targeted programs commercialize. Topical application captured 6.0% (Vyjuvek for dystrophic epidermolysis bullosa), and the residual 6.0% spans intratumoral, intracardiac, and intra-articular routes.
By Therapy Type
Gene replacement and augmentation therapies represented 58.0% of 2025 in vivo gene therapy revenue, anchored by AAV-delivered functional gene copies for monogenic disorders (Zolgensma SMN1, Hemgenix F9, Luxturna RPE65). Gene silencing therapies captured 18.0%, driven by AAV-mediated antisense oligonucleotide and shRNA approaches. In vivo gene editing (CRISPR base editing, prime editing) accounted for 12.0%, projected to grow fastest at 32.0% CAGR through 2034 as Verve Therapeutics, Beam Therapeutics, and Intellia advance pipeline programs. Oncolytic viral therapies (Imlygic and pipeline assets) covered 8.0%, and in vivo CAR-T plus other emerging therapy types accounted for the residual 4.0%.
By End-User
Hospitals and specialty clinics represented 53.7% of 2025 in vivo gene therapy end-user revenue, anchored by accredited gene therapy treatment centers across U.S. NCI-designated cancer centers, EU Centers of Excellence, and Japan's Hospital Network for Regenerative Medicine. Academic and research institutes captured 22.0%, projected to grow fastest at 26.6% CAGR through 2034 driven by NIH grant funding and clinical trial enrollment. Pharmaceutical and biotechnology companies represented 16.0%, anchored by in-house early-access programs and managed-access pathways. Cancer treatment centers and specialty pediatric hospitals together covered 8.3%, propelled by Zolgensma, Elevidys, and oncology in vivo CAR-T candidate programs.
Regional Analysis
North America led the global in vivo gene therapy market in 2025 with 45.0% share and USD 2.93 Billion in revenue, anchored by FDA-approved product franchises and the densest biotech capital base globally. The United States generated USD 2.65 Billion, supported by Zolgensma, Elevidys, Luxturna, Roctavian, Hemgenix, Kebilidi, Vyjuvek, Encelto, and Papzimeos commercial sales, plus more than 60 hospital systems with accredited gene therapy treatment programs. Canada contributed USD 0.22 Billion through Health Canada-approved labels for Zolgensma and Luxturna and a growing in vivo gene therapy clinical trial pipeline at SickKids Toronto and BC Children's Hospital. Mexico added USD 0.06 Billion via cross-border treatment access programs.
Europe accounted for 28.5% of the in vivo gene therapy market in 2025 with USD 1.85 Billion in revenue. Germany led the region with USD 0.55 Billion, propelled by EMA-approved Zolgensma reimbursement under the G-BA framework and the Charite Berlin and Heidelberg University in vivo gene therapy treatment centers. France contributed USD 0.32 Billion, anchored by HAS-approved labels and IGR Villejuif clinical infrastructure. The United Kingdom added USD 0.28 Billion through NICE-approved Zolgensma reimbursement and the Great Ormond Street Hospital pediatric gene therapy program. Italy generated USD 0.20 Billion via San Raffaele Hospital Milano. Spain delivered USD 0.16 Billion, and the Netherlands, Belgium, and the Nordics together accounted for USD 0.34 Billion. EU Horizon Europe ATMP research grants exceeding EUR 200 Million anchor regional supply-side R&D.
Asia Pacific captured 17.0% of the in vivo gene therapy market in 2025 with USD 1.11 Billion in revenue. Japan generated USD 0.42 Billion, supported by PMDA-approved Zolgensma, Luxturna, and Elevidys labels and the country's Act on the Safety of Regenerative Medicine. China contributed USD 0.32 Billion, propelled by the National Medical Products Administration accelerated approval pathways and domestic biotech programs at WuXi AppTec, Shanghai Belief BioMed, and Wuhan Neurophth. South Korea added USD 0.14 Billion via Samsung Biologics manufacturing capacity. India contributed USD 0.10 Billion through the CDSCO regulatory framework and AIIMS clinical infrastructure. Australia delivered USD 0.07 Billion, and Singapore, Taiwan, and ASEAN markets together accounted for USD 0.06 Billion.
Latin America held 5.5% of the in vivo gene therapy market in 2025 with USD 0.36 Billion in revenue. Brazil represented USD 0.18 Billion, the largest national market in the region, anchored by ANVISA-approved Zolgensma access and Hospital Israelita Albert Einstein gene therapy services. Mexico added USD 0.07 Billion through Cofepris managed access. Argentina, Chile, and Colombia together delivered USD 0.11 Billion via cross-border named-patient programs and clinical trial enrollment.
Middle East and Africa captured 4.0% of the in vivo gene therapy market in 2025 with USD 0.26 Billion in revenue. Saudi Arabia and the United Arab Emirates together delivered USD 0.16 Billion, supported by King Faisal Specialist Hospital and Cleveland Clinic Abu Dhabi gene therapy programs. Israel contributed USD 0.06 Billion through Sheba Medical Center and Hadassah-University Medical Center clinical infrastructure. South Africa added USD 0.02 Billion via Wits Health Consortium clinical trial enrollment, and Egypt, Turkey, and other markets together accounted for USD 0.02 Billion.
Country Analysis
The United States in vivo gene therapy market reached USD 2.65 Billion in 2025 with a 19.8% projected CAGR through 2034. The country anchors three structural pillars: FDA accelerated approval pathways that cleared Encelto and Papzimeos during 2025, the densest biotech capital base globally with USD 25 Billion-plus in cell-and-gene therapy venture funding through 2025, and academic medical center infrastructure (Boston Children's Hospital, Children's Hospital of Philadelphia, MD Anderson, Mayo Clinic, Memorial Sloan Kettering) that anchors clinical delivery. The Inflation Reduction Act drug pricing mechanisms and CMS coverage frameworks for Zolgensma, Elevidys, Hemgenix, and Roctavian shape U.S. reimbursement economics.
Germany's in vivo gene therapy market generated USD 0.55 Billion in 2025 with a 19.4% projected CAGR through 2034. The country hosts the densest European in vivo gene therapy infrastructure, anchored by Charite Universitatsmedizin Berlin, Heidelberg University Hospital, and Hannover Medical School treatment centers. The G-BA reimbursement framework provides full coverage for Zolgensma at approximately EUR 1.95 Million per dose, Roctavian at approximately EUR 2.7 Million, and Elevidys under managed-access pathways. The German Federal Ministry of Education and Research (BMBF) co-funds gene therapy research through the National Decade Against Cancer initiative. Bayer AG's BlueRock Therapeutics subsidiary anchors domestic in vivo platform investment.
Japan's in vivo gene therapy market reached USD 0.42 Billion in 2025 with a 19.0% projected CAGR through 2034. The country pairs an accelerated regulatory framework under the PMDA's conditional and time-limited approval pathway (Act on the Safety of Regenerative Medicine) with strong domestic manufacturing capability. PMDA-approved Zolgensma reimbursement at approximately JPY 167 Million per dose anchors the largest single line item. Japanese pharma incumbents Astellas Pharma, Takeda Pharmaceutical, and Daiichi Sankyo are advancing in vivo platform programs through internal R&D and select acquisitions, with Astellas's Audentes Therapeutics subsidiary serving as the principal in vivo gene therapy operating arm.
China's in vivo gene therapy market reached USD 0.32 Billion in 2025 with a 28.5% projected CAGR through 2034, the highest national CAGR globally. The country combines accelerated NMPA pathways with the world's largest patient pool for inherited retinal disease, hemophilia, and rare neurological conditions. Domestic biotech players including Wuhan Neurophth (ND4 mutation Leber Hereditary Optic Neuropathy), Shanghai Belief BioMed (BBM-H901 hemophilia B), and Frontera Therapeutics anchor the indigenous pipeline. WuXi Biologics and WuXi AppTec provide domestic AAV manufacturing capacity, while Samsung Biologics serves cross-border supply. The China Healthy Industry 2030 plan and Made in China 2025 advanced biomedicine pillar back national R&D funding exceeding RMB 80 Billion through 2030.
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
Pricing and Purchase Options
Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF).
TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
1.1. MARKET SNAPSHOT
1.2. KEY FINDINGS & INSIGHTS
1.3. ANALYST RECOMMENDATIONS
1.4. FUTURE OUTLOOK
2. RESEARCH METHODOLOGY
2.1. MARKET DEFINITION & SCOPE
2.2. RESEARCH OBJECTIVES: PRIMARY & SECONDARY DATA SOURCES
2.3. DATA COLLECTION SOURCES
2.3.1. COVERAGE OF 100+ PRIMARY RESEARCH/CONSULTATION CALLS WITH INDUSTRY STAKEHOLDERS
FIGURE 17 NORTH AMERICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 18 NORTH AMERICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 19 MARKET SHARE BY COUNTRY
FIGURE 20 LATIN AMERICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 21 LATIN AMERICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 22 MARKET SHARE BY COUNTRY
FIGURE 23 EASTERN EUROPE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 24 EASTERN EUROPE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 25 MARKET SHARE BY COUNTRY
FIGURE 26 WESTERN EUROPE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 27 WESTERN EUROPE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 28 MARKET SHARE BY COUNTRY
FIGURE 29 EAST ASIA AND PACIFIC IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 30 EAST ASIA AND PACIFIC IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 31 MARKET SHARE BY COUNTRY
FIGURE 32 SEA AND SOUTH ASIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 33 SEA AND SOUTH ASIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 34 MARKET SHARE BY COUNTRY
FIGURE 35 MIDDLE EAST AND AFRICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 37 NORTH AMERICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 38 U.S. IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 39 U.S. IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 40 CANADA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 41 CANADA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 42 LATIN AMERICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 43 MEXICO IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 44 MEXICO IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 45 BRAZIL IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 46 BRAZIL IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 47 ARGENTINA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 48 ARGENTINA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 49 COLUMBIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 50 COLUMBIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 51 REST OF LATIN AMERICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 52 REST OF LATIN AMERICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 53 EASTERN EUROPE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 54 POLAND IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 55 POLAND IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 56 RUSSIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 57 RUSSIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 58 CZECH REPUBLIC IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 59 CZECH REPUBLIC IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 60 ROMANIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 61 ROMANIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 62 REST OF EASTERN EUROPE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 63 REST OF EASTERN EUROPE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 64 WESTERN EUROPE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 65 GERMANY IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 66 GERMANY IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 67 FRANCE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 68 FRANCE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 69 UK IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 70 UK IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 71 SPAIN IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 72 SPAIN IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 73 ITALY IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 74 ITALY IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 75 REST OF WESTERN EUROPE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 76 REST OF WESTERN EUROPE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 77 EAST ASIA AND PACIFIC IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 78 CHINA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 79 CHINA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 80 JAPAN IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 81 JAPAN IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 82 AUSTRALIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 83 AUSTRALIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 84 CAMBODIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 85 CAMBODIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 86 FIJI IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 87 FIJI IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 88 INDONESIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 89 INDONESIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 90 SOUTH KOREA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 91 SOUTH KOREA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 92 REST OF EAST ASIA AND PACIFIC IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 93 REST OF EAST ASIA AND PACIFIC IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 94 SEA AND SOUTH ASIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 95 BANGLADESH IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 96 BANGLADESH IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 97 NEW ZEALAND IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 98 NEW ZEALAND IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 99 INDIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 100 INDIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 101 SINGAPORE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 102 SINGAPORE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 103 THAILAND IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 104 THAILAND IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 105 TAIWAN IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 106 TAIWAN IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 107 MALAYSIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 108 MALAYSIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 109 REST OF SEA AND SOUTH ASIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 110 REST OF SEA AND SOUTH ASIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 111 MIDDLE EAST AND AFRICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 112 GCC COUNTRIES IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 113 GCC COUNTRIES IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 114 SAUDI ARABIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 115 SAUDI ARABIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 116 UAE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 117 UAE IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 118 BAHRAIN IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 119 BAHRAIN IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 120 KUWAIT IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 121 KUWAIT IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 122 OMAN IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 123 OMAN IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 124 QATAR IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 125 QATAR IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 126 EGYPT IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 127 EGYPT IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 128 NIGERIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 129 NIGERIA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 130 SOUTH AFRICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 131 SOUTH AFRICA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 132 ISRAEL IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 133 ISRAEL IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 134 REST OF MEA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE TYPE ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 135 REST OF MEA IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE END USER ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 136 U. S. MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 137 U. S. MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 138 CANADA MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 139 CANADA MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 140 MEXICO MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 141 MEXICO MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 142 CHINA MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 143 CHINA MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 144 JAPAN MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 145 JAPAN MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 146 INDIA MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 147 INDIA MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 148 SOUTH KOREA MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 149 SOUTH KOREA MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 150 SAUDI ARABIA MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 151 SAUDI ARABIA MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 152 UAE MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 153 UAE MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 154 EGYPT MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 155 EGYPT MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 156 NIGERIA MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 157 NIGERIA MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 158 SOUTH AFRICA MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 159 SOUTH AFRICA MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 160 GERMANY MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 161 GERMANY MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 162 FRANCE MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 163 FRANCE MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 164 UK MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 165 UK MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 166 SPAIN MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 167 SPAIN MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 168 ITALY MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 169 ITALY MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 170 BRAZIL MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 171 BRAZIL MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 172 ARGENTINA MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 173 ARGENTINA MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 174 COLUMBIA MARKET SHARE ANALYSIS BY TYPE (2025)
FIGURE 175 COLUMBIA MARKET SHARE ANALYSIS BY END USER (2025)
FIGURE 176 IN VIVO GENE THERAPY MARKET CURRENT AND FUTURE MARKET KEY COUNTRY LEVEL ANALYSIS, 2025–2034, (USD MILLION)
FIGURE 177 FINANCIAL OVERVIEW:
Key Player Analysis
Novartis AG (NYSE: NVS), headquartered in Basel, Switzerland, holds the global leadership position in in vivo gene therapy through Zolgensma (onasemnogene abeparvovec), the AAV9-delivered one-time treatment for spinal muscular atrophy. Zolgensma is approved in more than 50 countries and has treated more than 4,000 patients globally since 2019 launch. Novartis reported fiscal 2024 net sales of USD 50.3 Billion across its branded medicines and Sandoz segments, with Zolgensma generating approximately USD 1.2 Billion in 2024 sales as the largest single in vivo gene therapy product by revenue.
Novartis's strategic profile in 2025 leaned on Zolgensma label expansion across European markets, continued PMDA regulatory engagement in Japan, and the broader Novartis Gene Therapies pipeline including OAV101 IT (intrathecal Zolgensma for older SMA patients). The competitive moat sits in scale manufacturing through the company's Libertyville, Illinois, and Durham, North Carolina facilities. Novartis holds a leading position based on installed treatment infrastructure across global pediatric SMA clinical centers, with pricing at approximately USD 2.25 Million per dose anchored by health-economic evidence of one-time-curative outcomes.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), headquartered in Cambridge, Massachusetts, holds the leadership position in in vivo gene therapy for Duchenne muscular dystrophy through Elevidys (delandistrogene moxeparvovec), the AAVrh74-delivered micro-dystrophin therapy. Sarepta reported fiscal 2024 product revenue of approximately USD 1.79 Billion across its DMD franchise (Exondys 51, Vyondys 53, Amondys 45, Elevidys), with Elevidys generating accelerating quarterly revenue through 2025. The company holds a leading position based on installed base across U.S. DMD treatment centers.
Sarepta's strategic profile in 2025 was reshaped by Elevidys label broadening across older ambulatory and non-ambulatory DMD patients, continued FDA engagement on confirmatory study designs, and the broader limb-girdle muscular dystrophy pipeline (SRP-9003 for LGMD2E/R4, SRP-9001 for DMD with optimization). Sarepta's manufacturing scale-up at its Burlington, Massachusetts facility supports global Elevidys supply. The competitive moat sits in DMD-specific clinical and regulatory expertise that pure-play AAV peers cannot replicate without disease-specialty operating depth.
Roche Holding AG (FRA: ROG) / Spark Therapeutics, headquartered in Basel, Switzerland and Philadelphia, Pennsylvania, holds the leadership position in inherited retinal disease in vivo gene therapy through Luxturna (voretigene neparvovec) for biallelic RPE65 mutation-associated retinal dystrophy. Spark was acquired by Roche during 2019 for USD 4.8 Billion and now operates as a Roche Pharma subsidiary. Roche reported fiscal 2024 group sales of approximately CHF 60.5 Billion across its Pharmaceuticals and Diagnostics segments, with Luxturna captured under Roche specialty pharmaceuticals.
Roche/Spark's strategic profile in 2025 leaned on Luxturna global label maintenance, continued ophthalmology pipeline development (SPK-7001 for choroideremia, SPK-3006 for Pompe disease), and broader hemophilia A platform investment. Roche's parallel CRISPR Therapeutics partnership for hemoglobinopathies extends in vivo CRISPR base editing optionality. The competitive moat sits in ophthalmology-specific delivery infrastructure and Roche's global commercial scale across more than 100 country markets.
AstraZeneca plc (LSE: AZN), headquartered in Cambridge, United Kingdom, holds an emerging leadership position in in vivo cell therapy through its Q2 2025 take-up of EsoBiotec, the Belgian biotech developing the Engineered NanoBody Lentiviral (ENaBL) platform. The arrangement was announced 17 March 2025 valued at up to USD 1 Billion (USD 425 Million upfront plus up to USD 575 Million milestone-contingent). AstraZeneca reported fiscal 2024 total revenue of USD 54.1 Billion across its Oncology, BioPharmaceuticals, and Rare Disease segments, with cell therapy captured under Oncology Hematology R&D.
AstraZeneca's strategic profile in 2025 was anchored by EsoBiotec absorption that brings the ENaBL in vivo lentiviral platform under company control, the parallel Alteogen oncology development arrangement, and the broader cell therapy ambition expressed by Susan Galbraith, Executive Vice President for Oncology Hematology R&D. EsoBiotec's lead candidate ESO-T01 targets BCMA-positive multiple myeloma cells in vivo through intravenous infusion, bypassing autologous CAR-T manufacturing. The competitive moat sits in scaled in vivo CAR-T economics that traditional autologous CAR-T players (Novartis, Gilead/Kite, BMS, Janssen/Legend) cannot replicate without lentiviral in vivo platform IP.
Market Key Players:
NOVARTIS AG
ROCHE / SPARK THERAPEUTICS
SAREPTA THERAPEUTICS, INC.
ASTRAZENECA PLC
CSL BEHRING
BIOMARIN PHARMACEUTICAL INC.
PTC THERAPEUTICS, INC.
UNIQURE N.V.
REGENXBIO INC.
KRYSTAL BIOTECH, INC.
PRECIGEN, INC.
NEUROTECH PHARMACEUTICALS, INC.
ASTELLAS PHARMA / AUDENTES THERAPEUTICS
BIOGEN INC.
AMGEN INC.
VIRONEXIS BIOTHERAPEUTICS
STYLUS MEDICINE
4D MOLECULAR THERAPEUTICS
VOYAGER THERAPEUTICS
BEAM THERAPEUTICS
VERVE THERAPEUTICS
INTELLIA THERAPEUTICS, INC.
EDITAS MEDICINE, INC.
ANDELYN BIOSCIENCES
WUHAN NEUROPHTH
SHANGHAI BELIEF BIOMED
FRONTERA THERAPEUTICS
ALNYLAM PHARMACEUTICALS, INC.
BLUEROCK THERAPEUTICS (BAYER AG)
Others
Drivers
Rising Prevalence of Genetic and Rare Diseases
The increasing prevalence of inherited genetic disorders, rare diseases, and chronic conditions is a primary driver of the global in vivo gene therapy market. Diseases such as hemophilia, spinal muscular atrophy, inherited retinal disorders, and certain metabolic conditions often lack curative treatment options through conventional therapies. In vivo gene therapy enables the direct delivery of therapeutic genes into a patient's body, offering the potential for long-term or even permanent correction of disease-causing genetic mutations. This transformative therapeutic approach has strengthened interest among healthcare providers, patients, and biotechnology companies seeking durable treatment alternatives.
Furthermore, the growing awareness of precision medicine and advances in genetic screening are facilitating earlier diagnosis of hereditary disorders, thereby expanding the eligible patient population for gene-based therapies. Governments, healthcare organizations, and patient advocacy groups are also supporting rare disease research through funding initiatives and regulatory incentives, encouraging developers to accelerate clinical programs. As diagnosis rates improve and clinical evidence continues to demonstrate favorable long-term outcomes, demand for in vivo gene therapy solutions is expected to rise steadily across multiple therapeutic areas.
Advancements in Vector Technologies and Regulatory Support
Continuous innovation in viral and non-viral vector technologies is significantly enhancing the safety, targeting capability, and therapeutic efficiency of in vivo gene therapies. Improved adeno-associated virus (AAV), lentiviral vectors, and emerging lipid nanoparticle-based delivery platforms have increased gene transfer efficiency while reducing immunogenicity and off-target effects. These technological improvements have expanded the feasibility of treating a broader range of diseases, including neurological, cardiovascular, ophthalmic, and liver disorders, thereby accelerating commercial development across the market.
In parallel, regulatory agencies across major healthcare markets are implementing expedited approval pathways and orphan drug incentives for innovative gene therapies addressing unmet medical needs. Faster review timelines, supportive clinical guidance, and increased collaboration between regulators and developers are reducing commercialization barriers. At the same time, growing investment from pharmaceutical companies, venture capital firms, and strategic partnerships is strengthening research pipelines and manufacturing capabilities, enabling the market to transition from experimental therapies toward broader clinical adoption.
Restraints
High Treatment Costs and Manufacturing Complexity
One of the most significant restraints affecting the global in vivo gene therapy market is the exceptionally high cost associated with research, manufacturing, clinical development, and commercialization. Producing high-quality viral vectors requires sophisticated manufacturing infrastructure, specialized quality control procedures, and stringent regulatory compliance, substantially increasing production expenses. Consequently, many approved gene therapies are priced at premium levels, limiting affordability for healthcare systems and restricting patient access, particularly in low- and middle-income countries.
Additionally, manufacturing scalability remains a considerable challenge as demand for commercial gene therapies continues to increase. Maintaining batch consistency, ensuring vector purity, and meeting global regulatory standards require substantial capital investments and highly skilled technical expertise. Limited manufacturing capacity and complex supply chain requirements often contribute to product shortages and delayed commercialization timelines, slowing overall market expansion despite growing clinical demand.
Safety Concerns and Regulatory Challenges
Although in vivo gene therapy has demonstrated remarkable therapeutic potential, concerns regarding long-term safety continue to limit widespread adoption. Immune responses against viral vectors, unintended genetic modifications, and variability in therapeutic expression remain important clinical considerations. Long-term patient monitoring is often required to evaluate treatment durability and identify delayed adverse events, creating additional complexities for healthcare providers and regulatory authorities.
Moreover, regulatory approval processes for gene therapies remain highly rigorous due to the novelty and complexity of these treatments. Developers must generate extensive preclinical and clinical evidence demonstrating safety, efficacy, manufacturing consistency, and long-term follow-up outcomes. Regulatory expectations may differ across regions, increasing compliance costs and prolonging product development timelines. These challenges can delay market entry for innovative therapies and discourage smaller biotechnology companies with limited financial resources.
Opportunities
Expansion into New Therapeutic Indications
The expanding understanding of disease genetics is creating substantial opportunities for the global in vivo gene therapy market beyond traditional rare genetic disorders. Researchers are increasingly investigating gene therapies for more prevalent diseases, including cardiovascular disorders, neurodegenerative diseases, autoimmune conditions, and selected forms of cancer. Successful expansion into these larger patient populations could significantly increase the commercial potential of in vivo gene therapy while transforming treatment paradigms for diseases that currently rely on lifelong symptom management.
At the same time, advances in genome editing technologies, next-generation vectors, and tissue-specific delivery systems are broadening the range of treatable conditions. Enhanced targeting precision and improved therapeutic durability are expected to increase physician confidence and support wider clinical adoption. As ongoing clinical trials continue to generate positive efficacy and safety data across diverse indications, pharmaceutical companies are likely to accelerate pipeline diversification and expand global commercialization efforts.
Emerging Markets and Strategic Collaborations
Emerging healthcare markets present significant growth opportunities as governments continue investing in biotechnology infrastructure, genomic medicine programs, and advanced healthcare services. Countries across Asia-Pacific, Latin America, and the Middle East are strengthening regulatory frameworks, supporting local clinical research, and expanding access to precision medicine. Improving healthcare infrastructure and increasing awareness of genetic diseases are expected to create favorable conditions for future adoption of in vivo gene therapies in these regions.
In addition, strategic collaborations between biotechnology companies, pharmaceutical manufacturers, academic institutions, and contract development organizations are accelerating innovation throughout the value chain. Partnerships enable technology sharing, manufacturing expansion, clinical trial collaboration, and commercialization support while reducing development risks and costs. As companies continue pursuing licensing agreements, co-development partnerships, and regional distribution alliances, these collaborative strategies are expected to strengthen market penetration and facilitate broader patient access worldwide.
Trends
Growing Adoption of Precision Medicine and Personalized Therapies
A major trend shaping the global in vivo gene therapy market is the increasing integration of precision medicine into clinical practice. Healthcare providers are increasingly utilizing genomic sequencing, biomarker identification, and molecular diagnostics to tailor treatments according to individual patient profiles. In vivo gene therapy aligns closely with this personalized healthcare approach by targeting the underlying genetic causes of disease rather than simply managing symptoms, resulting in improved therapeutic outcomes and potentially long-lasting clinical benefits.
The continued decline in genomic sequencing costs and the expansion of genetic testing services are supporting earlier disease identification and more accurate patient selection for gene therapy. Pharmaceutical companies are also incorporating companion diagnostics into clinical development programs to improve treatment effectiveness and optimize regulatory approval strategies. This growing emphasis on personalized medicine is expected to remain a key trend driving future innovation within the market.
Innovation in Gene Delivery Platforms and Commercial Expansion
Rapid innovation in gene delivery technologies continues to reshape the competitive landscape of the in vivo gene therapy market. Developers are investing in next-generation viral vectors, engineered capsids, lipid nanoparticles, and hybrid delivery systems designed to improve tissue specificity, minimize immune responses, and enable repeat dosing. These technological advancements are expanding therapeutic possibilities while addressing several limitations associated with first-generation delivery platforms.
Simultaneously, the market is witnessing increasing commercial activity through strategic acquisitions, licensing agreements, manufacturing expansion, and global product launches. Large pharmaceutical companies are strengthening their gene therapy portfolios by partnering with innovative biotechnology firms possessing specialized platform technologies. Combined with expanding manufacturing investments and growing clinical trial activity worldwide, these developments are accelerating commercialization and positioning in vivo gene therapy as a rapidly evolving segment within advanced therapeutics.
Investment & M&A Activity
The in vivo gene therapy market recorded approximately USD 6.20 Billion in disclosed M&A and funding activity over the trailing 12 months ending April 2026, reflecting blue-chip pharma consolidation around in vivo platforms and venture-backed expansion in in vivo CAR-T and engineered capsid programs. Capital concentration migrated toward platform acquisitions and strategic-investor participation rather than seed-stage deals as scale players aim to absorb in vivo IP.
During Q2 2025, AstraZeneca closed the take-up of EsoBiotec for up to USD 1 Billion (USD 425 Million in cash upfront plus up to USD 575 Million in development and regulatory milestone payments), per the announcement on 17 March 2025. The arrangement gives AstraZeneca control of the ENaBL in vivo lentiviral platform and lead candidate ESO-T01 for multiple myeloma. EsoBiotec investors Invivo Partners and UCB Ventures retain milestone-payment exposure. AstraZeneca later expanded oncology partnerships with Alteogen during 2025, building a broader in vivo platform anchor.
During May 2025, Stylus Medicine launched with USD 85 Million to advance precision in vivo genetic therapies and scaled in vivo CAR-T programs that bypass ex vivo gene editing manufacturing bottlenecks. Industry-wide capital activity included Pfizer's 2025 exit from gene therapy with Beqvez discontinuation, signaling a broader rebalancing toward proven scale platforms. Andelyn Biosciences broadened its AAV Curator platform via Stanton Lab CNS capsid licensing during February 2025. Verve Therapeutics, Beam Therapeutics, and Intellia Therapeutics together raised more than USD 1.50 Billion in capital across 2024-2025 for in vivo CRISPR base editing programs targeting cardiovascular, hepatic, and CNS indications.
Recent Developments
August 2025 | Precigen Papzimeos U.S. Approval
During August 2025, Precigen earned U.S. FDA clearance for Papzimeos (zopapogene imadenovec) for the treatment of HPV-related recurrent respiratory papillomatosis. The therapy uses a gorilla adenovirus vector to deliver tumor-specific antigens that prime the immune system against HPV-infected cells, opening a new in vivo gene therapy modality combining viral vector delivery with cancer immunotherapy.
Strategic Impact: Papzimeos approval validates non-AAV viral vector platforms for in vivo cancer immunotherapy applications and expands the addressable market for Precigen's UltraVector and AdenoVerse platforms beyond rare disease into oncology indications.
May 2025 | Stylus Medicine Launch
During May 2025, Stylus Medicine launched with USD 85 Million in capital to advance precision in vivo genetic therapies. The platform aims to improve the accuracy and scale of gene integration, accelerating the development of one-time-curative in vivo gene therapies and improving the efficiency of in vivo CAR-T programs.
Strategic Impact: Stylus Medicine's launch capital signals continued venture interest in in vivo platforms despite Pfizer's 2025 exit, building venture-backed alternatives to AstraZeneca-EsoBiotec and Verve Therapeutics for newer in vivo gene therapy modalities.
March 2025 | AstraZeneca-EsoBiotec Acquisition
On 17 March 2025, AstraZeneca disclosed its take-up of Belgian biotech EsoBiotec for up to USD 1 Billion (USD 425 Million in cash upfront plus up to USD 575 Million in development and regulatory milestone payments). The arrangement closed during Q2 2025 and brings the Engineered NanoBody Lentiviral (ENaBL) in vivo cell therapy platform under AstraZeneca control.
Strategic Impact: The transaction marks the largest blue-chip pharma in vivo cell therapy take-up to date, validating in vivo CAR-T economics versus traditional autologous manufacturing and pressuring competitors to make similar platform commitments through 2026-2028.
March 2025 | Neurotech Encelto U.S. Approval
On March 2025, Neurotech Pharmaceuticals received U.S. FDA clearance for Encelto (revakinagene taroretcel) for the treatment of macular telangiectasia type 2. The therapy uses an encapsulated cell technology platform delivering ciliary neurotrophic factor to retinal cells through a surgically implanted device, broadening the in vivo gene therapy ophthalmology menu.
Strategic Impact: Encelto approval opens an estimated USD 0.40 Billion addressable market for macular telangiectasia type 2 in the U.S. alone and validates Neurotech's encapsulated cell technology for additional retinal indications including geographic atrophy and inherited retinal dystrophies.
February 2025 | Andelyn Biosciences AAV Curator Expansion
During February 2025, Andelyn Biosciences broadened its AAV Curator platform via a licensing arrangement with Stanton Lab for CNS-targeted capsids. The arrangement supports external R&D services for client gene therapy developers seeking engineered AAV capsids that improve blood-brain-barrier penetration for neurodegenerative indications.
Strategic Impact: CNS-capsid licensing extends Andelyn's competitive positioning in the AAV manufacturing services market versus Catalent, Lonza, and Forge Biologics, opening higher-margin engineered-capsid revenue streams for upcoming CNS-targeted in vivo gene therapy programs.
January 2025 | Pfizer Beqvez Discontinuation
During January 2025, Pfizer disclosed the discontinuation of Beqvez (fidanacogene elaparvovec), its FDA-approved hemophilia B in vivo gene therapy, citing slow market uptake despite full regulatory approval. Pfizer's exit leaves the company without active in vivo gene therapy assets and follows similar challenges at BioMarin Roctavian and CSL Behring Hemgenix.
Strategic Impact: The Beqvez discontinuation signals that approval alone does not guarantee commercial success in hemophilia gene therapy and raises questions about long-term blue-chip pharma investment in single-indication in vivo gene therapy assets without supporting platform economics.
Frequently Asked Questions
How big is the In Vivo Gene Therapy Market?
The global in vivo gene therapy market was valued at USD 5.43 Billion in 2024 and USD 6.50 Billion in 2025, reaching USD 32.50 Billion by 2034 at a CAGR of 19.6% during 2026–2034. Explore market size, trends, drivers, opportunities, and growth analysis.
Who are the major players in the In Vivo Gene Therapy Market?
Which segments covered the In Vivo Gene Therapy Market?
By Vector Type, (AAV Vectors, Adenoviral Vectors, Lentiviral Vectors, Retroviral Vectors, HSV Vectors, Non-Viral Vectors), By Indication, (Oncology, Neurological Disorders, Rare Genetic Disorders, Ophthalmic Disorders, Cardiovascular Diseases, Infectious Diseases, Others), By Route of Administration, (Intravenous (IV), Intramuscular (IM), Intrathecal, Intravitreal, Intratumoral, Others), By Therapy Type, (Gene Augmentation, Gene Silencing, Gene Editing, Immunogene Therapy), By End-User, (Hospitals, Specialty Clinics, Research Institutes, Academic Centers, Others),
How can this market research report help my business make strategic decisions?
Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.
How frequently is the data updated?
We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.
Aerospace And Defence
Agriculture
Automotive And Transportation
Banking And Finance
Business
Chemicals And Materials
Consumer And Retail
Electronics And Semiconductors
Food And Beverages
Machinery & Equipments
Manufacturing And Construction
Medical Devices
Others
Pharmaceuticals And Healthcare
Power And Energy
Sports
Technology
